|
Atomistry » Chlorine » PDB 4ylc-4ywq » 4ytf | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atomistry » Chlorine » PDB 4ylc-4ywq » 4ytf » |
Chlorine in PDB 4ytf: Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune DiseasesEnzymatic activity of Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune Diseases
All present enzymatic activity of Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune Diseases:
2.7.10.2; Protein crystallography data
The structure of Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune Diseases, PDB code: 4ytf
was solved by
L.Farmer,
M.W.Ledeboer,
H.J.Zuccola,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Other elements in 4ytf:
The structure of Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune Diseases also contains other interesting chemical elements:
Chlorine Binding Sites:
The binding sites of Chlorine atom in the Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune Diseases
(pdb code 4ytf). This binding sites where shown within
5.0 Angstroms radius around Chlorine atom.
In total only one binding site of Chlorine was determined in the Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune Diseases, PDB code: 4ytf: Chlorine binding site 1 out of 1 in 4ytfGo back to![]() ![]()
Chlorine binding site 1 out
of 1 in the Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune Diseases
![]() Mono view ![]() Stereo pair view
Reference:
L.J.Farmer,
M.W.Ledeboer,
T.Hoock,
M.J.Arnost,
R.S.Bethiel,
Y.L.Bennani,
J.J.Black,
C.L.Brummel,
A.Chakilam,
W.A.Dorsch,
B.Fan,
J.E.Cochran,
S.Halas,
E.M.Harrington,
J.K.Hogan,
D.Howe,
H.Huang,
D.H.Jacobs,
L.M.Laitinen,
S.Liao,
S.Mahajan,
V.Marone,
G.Martinez-Botella,
P.Mccarthy,
D.Messersmith,
M.Namchuk,
L.Oh,
M.S.Penney,
A.C.Pierce,
S.A.Raybuck,
A.Rugg,
F.G.Salituro,
K.Saxena,
D.Shannon,
D.Shlyakter,
L.Swenson,
S.K.Tian,
C.Town,
J.Wang,
T.Wang,
M.W.Wannamaker,
R.J.Winquist,
H.J.Zuccola.
Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor For the Treatment of Autoimmune Diseases. J.Med.Chem. V. 58 7195 2015.
Page generated: Fri Jul 26 04:15:52 2024
ISSN: ISSN 0022-2623 PubMed: 26230873 DOI: 10.1021/ACS.JMEDCHEM.5B00301 |
Last articlesCl in 6COGCl in 6CST Cl in 6CTW Cl in 6CTZ Cl in 6CTT Cl in 6CSP Cl in 6CU9 Cl in 6CTX Cl in 6CTU Cl in 6CTP |
© Copyright 2008-2020 by atomistry.com | ||
Home | Site Map | Copyright | Contact us | Privacy |